The partners said a TROP2-targeting antibody drug conjugate succeeded in a late-stage trial, paving the way for potential ...
Top executives can steer large pharma companies in many ways. Here are the ones who employees approve of the most.
Itvisma, an intrathecal version of Zolgensma, can be used in children, teens and adults to stabilize or improve motor ...
The company, which invested heavily in oncology in recent years, has now put more than $400 million on the table to access a ...
Newly launched Dayra Therapeutics has agreed to identify for Biogen "oral macrocycle candidates" that go after "high-priority ...
Asundexian's Phase 3 study results raise hopes for a new class of cardiovascular drugs that has seen clinical setbacks.
The agency is evaluating whether further regulatory action is warranted after receiving reports of neutralizing antibodies.
The studies offer perhaps the most concrete rebuttal yet to an idea that GLP-1 drugs, which have profound benefits on weight ...
It’s well known that AD has a strong genetic component. Apolipoprotein E (APOE4) is expressed in 40% to 65% of all AD ...
As Anaptysbio seeks to split off a royalty business, both companies claim the other breached contracts surrounding ...
The pharmaceutical company’s success developing medicines for obesity has swelled its worth to levels associated with tech titans like Apple and Google and dwarfed that of its drugmaking peers.
The FDA will now allow biotechs to ask agency staff for “quick clarifications” via email. Elsewhere, Novartis hiked guidance for two top drugs and a startup nearing “unicorn” status secured a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback